Supply Chain Archives

07/30/2025
Beyond Logistics: Why Clinical Trial Success Depends on a Connected Supply Chain Strategy
Contract Research Organizations (CROs) are the orchestrators of modern clinical trials. From protocol development to site management and data collection, they serve as the hidden infrastructure that brings therapies from bench to bedside. But in the increasingly global and complex research landscape, a CRO’s ability to execute doesn’t just depend on clinical expertise, it hinges on the strength of the supply chain supporting every material movement and site milestone.
07/28/2025
Turning Risk into Resilience with Supply Chain Resilience for CDMOs
Contract Development and Manufacturing Organizations (CDMOs) are under more pressure than ever to deliver reliable results in an unpredictable world. From geopolitical instability to material shortages to increasingly complex regulatory expectations, the risks facing clinical and commercial programs have intensified. For CDMOs, these risks don’t just affect their own operations, they directly impact their clients’ ability to bring therapies to patients.
07/25/2025
Scaling with Confidence for CDMO Supply Chain Alignment
Contract Development and Manufacturing Organizations (CDMOs) play a critical role in the life sciences industry, enabling biopharma innovators to bring new therapies from development to manufacturing to patients around the world. The demand placed on CDMOs has only increased in recent years, especially as cell, gene, and biologic therapies have moved from concept to clinic at unprecedented speeds. While the technical and scientific capabilities of CDMOs have advanced to meet these challenges, one area remains a frequent source of friction and delay...the end-to-end, temperature-controlled supply chain.
07/24/2025
Building Better CDMO Supply Chain Readiness
With the accelerating growth of advanced therapies comes increasing complexity in the developing and manufacturing ecosystem. Contract Development and Manufacturing Organizations (CDMOs) sit at the center of this growth, providing critical manufacturing and development services on behalf of their clients, the therapeutic developers. CDMOs require the infrastructure and processes to efficiently scale production, maintain timelines, and ensure product integrity, all while navigating evolving regulatory expectations.
06/24/2025
When Every Hour Counts: How Cryoport Systems Rapidly Mobilized to Protect INmune Bio’s Critical Clinical Materials
Biopharmaceutical development, particularly for advanced CGTs, relies on a robust infrastructure of logistics, BioServices, and temperature-controlled supply chains to ensure timely and intact delivery of drug products under stringent regulations. INmune Bio Inc. faced a challenge when a sudden biostorage site closure jeopardized a key clinical trial. However, with a strong support network, they turned to established partners like Cryoport Systems to overcome the crisis.
06/04/2025
Engineering for Impact: A Conversation with Mike Dybicz on the HV3 and Safepak Systems
When it comes to cell and gene therapy (CGT) logistics, innovation is about more than improving efficiency, it’s about safeguarding a patient’s only chance at treatment. We sat down with Mike Dybicz, Senior Vice President & Chief Product Development Officer, to discuss how Cryoport Systems is reshaping the future of CGT logistics with innovative products such as Cryoport Express® Cryogenic HV3 Shipping System and Safepak® System 1800, designed specifically to reduce risk, increase reliability, and ultimately improve patient outcomes.
03/12/2025
Global Experts, Local Presence: Strengthening Europe’s Advanced Therapy Supply Chain
The development and commercialization of Advanced Therapy Medicinal Products (ATMPs) in Europe require a highly coordinated supply chain. From temperature-controlled logistics and biostorage to regulatory compliance, every stage of the ATMP lifecycle depends on precision, reliability, and risk mitigation
03/04/2025
How Our Recent Innovative Solutions Meet Today’s Supply Chain Challenges
When advanced therapy organizations place innovation at the center of their approach to solving supply chain challenges, they prioritize the most important person involved – the waiting patient. An innovative, patient-centric approach reframes obstacles to focus on solutions that can ensure the vitality and protection of sensitive materials throughout every stage and phase of the journey to the patient’s bedside.
02/12/2025
Ensuring Patient Impact in Advanced Therapy Logistics: A Conversation with Cryoport Systems’ Experts
The logistics behind advanced therapies aren’t just about moving shipments from point A to point B, they’re about protecting the integrity of life-saving treatments and ensuring that patients receive them without compromise. Following their discussion at Advanced Therapies Week 2025, we sat down with Aruna Mor, Chief Commercial Officer, and Mike Dybicz, Senior Vice President & Chief Product Development Officer, to dive deeper into how Cryoport Systems prioritizes patient impact at every step of the supply chain.
02/12/2025
Advancing Cell and Gene Therapy on International Childhood Cancer Day
Every year on February 15th, International Childhood Cancer Day (ICCD) serves as a global platform to raise awareness about childhood cancer, advocate for improved access to care, and highlight the need for continued research and innovation. Pediatric cancer remains one of the leading causes of death among children worldwide, with approximately 400,000 new cases diagnosed each year.Categories
- All (60)
- Industry Insights (18)
- Managing the Cold Chain (27)
- Navigating Logistics (24)
- Patient Access and Awareness (8)
Tags
- Asia
- Biologics
- BioServices
- Biostorage
- CDMOs
- Cell Therapy
- Clinical Trials
- Cold Chain Management
- Commercialization
- CROs
- Cryopreservation
- Europe
- Gene Therapy
- Global Logistics Tracking
- Global Supply Chain Management
- International Shipping
- North America
- Risk Mitigation
- Standards and Compliance
- Supply Chain Management